TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Predictive Role of MIDAS Reduction at 3 Months for Erenumab Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of CM according to ICHD-3 criteria for at least 12 months prior to enrollment;~* completion of a full headache diary in the 3 months preceding the enrollment; compliance to complete a daily headache diary for 1 year;~* previous failure of at least 3 classes of preventive treatments among beta-blockers, antiepileptic drugs, antidepressants, or onabotulinumtoxin-A;~* MIDAS score \> 11.~Exclusion Criteria:~* severe cardiologic comorbidities;~* pregnancy and breastfeeding;~* previous adverse reaction to latex

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects at least 12 years old and in good general health.~* Mild to moderate plaque-type psoriasis~Exclusion Criteria:~* Known allergy or other adverse reaction to calcipotriene or other vitamin D analogs; or to any component of the investigational formulations~* History of hypercalcemia or of vitamin D toxicity.~* Diagnosis of generalized pustular or erythrodermic exfoliative psoriasis.~* Other serious skin disorder or any chronic medical condition that is not well controlled.~* Use of non-biologic systemic anti-psoriatic therapy or biologic therapy within four weeks of enrollment.~* Use of topical therapies that have a known beneficial effect on psoriasis, within 2 weeks of enrollment.~* Systemic medications for other medical conditions that are known to affect psoriasis within the past four weeks of enrollment.~* Use of any investigational therapy within 4 weeks of enrollment.~* Pregnant women, women who are breast feeding, or sexually active women of child bearing potential who are not practicing an acceptable method of birth control.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- U0267 Foam (Type: EXPERIMENTAL): U0267 is a vitamin D3 analog (calcipotriene) foam. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
- Vehicle foam (Type: PLACEBO_COMPARATOR): Vehicle foam is the same as the U0267 foam except that it does not have the active ingredient. It is applied twice a day for 8 weeks to psoriasis lesions on the body.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with Non-Erosive Gastroesophageal Reflux Disease identifying their main symptom as heartburn.~  * History of episodes of heartburn for 6 months or longer prior to screening.~ * History of episodes of heartburn for 4 or more days during the 7 days prior to Day -1 as recorded in the electronic diary.~Exclusion Criteria:~* Use of prescription or non-prescription proton pump inhibitors (PPIs), histamine (H2) receptor antagonists, sucralfate, misoprostol or prokinetics throughout the study~* Erosive Esophagitis seen on endoscopy during study screening.~* Co-existing diseases affecting the esophagus.~* Abnormal laboratory values that suggest significant clinical disease.~* Known acquired immunodeficiency syndrome (AIDS)~* Females pregnant or lactating.~* History of Alcohol abuse.~* History of Cancer within 3 years prior to screening.~* Chronic (\>12 doses per month) use of nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclo-oxygenase-2 (COX-2) inhibitors~* Use of antacids (except for study supplied Gelusil® )~* Use of drugs with significant anticholinergic effects~* Need for continuous anticoagulant (blood thinner) therapy~* Endoscopic Barrett's esophagus and/or definite dysplastic changes in the esophagus~* History of dilatation of esophageal strictures, other than a Schatzki's ring (a ring of mucosal tissue near the lower esophageal sphincter)~* Current or historical evidence of Zollinger-Ellison syndrome or other hypersecretory condition~* History of gastric, duodenal or esophageal surgery except simple oversew of an ulcer~* Subjects who, in the opinion of the investigator, are unable to comply with the requirements of the study or are unsuitable for any reason.~* Acute upper gastrointestinal (UGI) hemorrhage within 4 weeks of the Screening endoscopy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexlansoprazole MR 60 mg QD (Type: EXPERIMENTAL): None
- Dexlansoprazole MR 90 mg QD (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Obese, defined as BMI ≥ 30 kg/m2, at both time of abdominal fat imaging and at study entry.~* Ages 30-65~* No prevalent diagnosis of type 2 diabetes mellitus, either at the time of abdominal fat imaging or at study entry.~* Previous abdominal fat quantification by magnetic resonance imaging in the Dallas Heart Study or possible neck-to-knee MRI for VAT measurement may be performed.~Exclusion Criteria:~* Pregnant or breastfeeding~* Incarcerated~* Chronic kidney or liver disease~* History of frequent (\>2/year) urinary tract infections~* Non-obese either at time of abdominal fat imaging or at present.~* Greater than 10% change in body weight (kg) between time of abdominal fat imaging and present.~* Has donated blood within last 6 weeks~* Cannot give informed consent, understand the protocol, or tolerate any aspect of the protocol~* If undergoing MRI, persons with metal implants contraindicated for 3Tesla MRI exams will be excluded. Severe claustrophobia will also be assessed prior to an MRI exam.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Empagliflozin (Type: EXPERIMENTAL): Empagliflozin 10 mg by mouth daily for 3 months.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo one tablet daily for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing radiofrequency catheter ablation for scar VT which includes VT secondary to ischemic cardiomyopathy and non-ischemic cardiomyopathy~* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 24 hours prior to the start of study drug~* Women must not be breastfeeding~* WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with Apixaban plus 33 days post-treatment completion~* Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment and for a total of 93 days post-treatment completion~* Participants must agree to the use of one approved method of contraception~Exclusion Criteria:~* History of cerebral vascular accident/transient ischemic attack (CVA/TIA) in last 3 months~* Cardiac surgery or neurosurgery within 3 months of the intended procedure date~* Any active bleeding~* Severe hypersensitivity reaction to ELIQUIS (including drug hypersensitivity, such as skin rash and allergic reactions)~* Participants cannot have prosthetic heart valves~* History or bleeding and clotting disorders~* Contraindications to Aspirin therapy~* Contraindication to oral anticoagulation~* Patient on an anticoagulant prior to the ablation for other primary indications like atrial fibrillation (AF), deep vein thrombosis (DVT) or a mechanical valve~* Evidence of intracardiac thrombus~* Patient with Creatinine Clearance of \< 30 cc/min~* Participation in another investigational study related to oral anticoagulation, drug and/or device intervention~* Claustrophobic patients~* Implantable Cardioverter Defibrillator (ICD) generator placement before the year 2000~* Has an ICD and is pacing dependent without underlying rhythm upon interrogation at baseline~* Patient has abandoned leads~* Patients who are on p-glycoprotein inducers or inhibitors where the dose of Apixaban cannot be effectively altered

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- DOAC (Direct Oral Anticoagulant) (Type: EXPERIMENTAL): Participants will be asked to take standard dose approved for stroke prophylaxis
- Aspirin (Type: ACTIVE_COMPARATOR): Participants will be asked to take 81 milligrams by mouth once per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Health Impact of Treating and Safely Storing Shallow Tubewell Drinking Water

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Using a shallow tubewell that is free from iron complaints as the bari's primary source of drinking water and~* Having a child between the ages of six months and two years living in the bari~Exclusion Criteria:~* Iron complaints of the shallow tubewell

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- Aquatabs and Safe Storage Vessel (Type: EXPERIMENTAL): Households in this group will receive Aquatabs for water purification, a safe water storage container to prevent contamination during storage in the home, and training and encouragement to treat and safely store their water using the provided products.
- Safe Storage Vessel (Type: EXPERIMENTAL): Households in this group will receive a safe water storage container, and training and encouragement to safely store their water using the provided products. If our study shows that treatment of tubewell water at the household level is effective in protecting children's health, they will receive a six-month supply of water treatment tablets at the end of the study.
- Standard practice (Type: OTHER): Households in this group will not receive any water treatment or storage intervention during the study. They will continue their usual water collection and storage practices. If our study shows that treatment and safe storage of tubewell water at the household level is effective in protecting children's health, they will receive the same safe water storage container as Groups 1 and 2 as well as a six-month supply of water treatment tablets at the end of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Influence of Postoperative Analgesia on Systemic Inflammatory Response and POCD After Femoral Fractures Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients age 65 and over~* fracture of the proximal femur~* preoperative assessment American Society of Anesthesiologists(ASA) score I - ASA III~* a written consent of the patient to participate in research~Exclusion Criteria:~* patient non-compliance~* ASA status IV and IV above~* patients younger than 65 years~* dementia, Parkinson's disease, cerebrovascular accident history; simultaneous head injuries,the use of opioids and benzodiazepines longer than a month before the surgery; alcoholism; serious liver disease (class C according to Child-Pugh's classification); severe kidney disease that require dialysis~* result of MMSE test (Mini-Mental State Examination) under 17~* the existence of any contraindications for the implementation of regional anesthesia and one or other form of post-operative analgesia.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- morphine (Type: ACTIVE_COMPARATOR): The patient-controlled intravenous analgesia with morphine (basal flow of 0.5-2 mg / h, bolus dose of 0.5 mg, lockout interval of 20 minutes, hour limit of 3 doses), which will be carried out 72 hours after the surgery
- levobupivacaine (Type: ACTIVE_COMPARATOR): Upon completion of the operation for a period of 72 hours will be implemented continuous epidural local anesthetic through the Patient Controlled Analgesia (PCA) pump (Levobupivacaine 0.125%, basal flow of 6 ml / hour, a bolus dose of 2 ml, lockout interval of 20 minutes, hour limit of 3 doses).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Spironolactone in Cameroonian Diabetic Patients With Resistant Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Resistant hypertension~* Diabetes mellitus~Exclusion Criteria:~* T2DM with overt acute/chronic complications,~* serum potassium ≥ 5.5 mmol/l,~* estimated Glomerular Filtration Rate (eGFR) calculated using the Modification of Diet in Renal Disease formula ≤ 30 ml/min/1.73m² of body weight,~* absolute contraindication to any of the drug regimen of the trial,~* and current aldosterone antagonist treatment or cessation within the last 15 months

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Low dose Spironolactone (Type: EXPERIMENTAL): Add-on low dose 25 mg Spironolactone to current hypertension treatment
- Routine (Type: ACTIVE_COMPARATOR): Routine intensification of anti hypertensive treatment based on existing guidelines

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A subject must meet the following criteria to be eligible for inclusion in the study:~  1. Enrolled and Completed VISTA DME (VGFT-OD-1009) clinical trial~ 2. Willing and able to comply with clinic visits and study-related procedures~ 3. Provide signed informed consent~ 4. Enrollment in the trial within 12 weeks of trial activation.~Exclusion Criteria:~* A subject who meets any of the following criteria will be excluded from the study:~  1. Prior treatment with anti-VEGF therapy in the study eye within 28 days of baseline~ 2. Pregnant or breast-feeding women~ 3. Sexually active men\* or women of childbearing potential\*\* who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device \[IUD\]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly).~     * Contraception is not required for men with documented vasectomy. \*\*Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PRN (pro re nata) (Type: OTHER): 2 mg intravitreal aflibercept (Eylea) PRN, focal laser administered based on pre-specified criteria, 104 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TRANSDERMAL HRT RELIEVING POSTMENOPAUSAL SYMPTOMS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 1) last menstrual period between 6 months and 3 years before the beginning of the study plus follicle-stimulating hormone (FSH) levels higher than 35 IU/L; 2) age between 51 and 70 years; 3) no use of any medication known to interfere with hormonal levels in the past 6 months.~Exclusion Criteria:~* Patients presenting diabetes, previous hysterectomy, endometrial thickness higher than 5 mm, history of cancer, thromboembolism or established cardio vascular disease were excluded.

- Gender: FEMALE
- Minimum Age: 51 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bupropion SR Plus Counseling for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Smoke 10 or more cigarettes per day~* Expired carbon monoxide (CO) level greater than 9 parts per million (ppm)~* Motivated to quit smoking (score of 3 on 4-point self-report scale)~* Willing to fulfill study requirements~Exclusion Criteria:~* Carbon monoxide breath test score below 9 ppm~* Serious psychopathology (bipolar disorder, psychosis)~* Center for Epidemiologic Studies Depression Scale CES-D)score over 16~* Contraindications for use of bupropion~* History of seizure disorder~* History of eating disorder~* Current heavy drinking~* Risk of pregnancy~* Current breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Active bupropion + counseling (Type: ACTIVE_COMPARATOR): Active bupropion SR plus eight 10-minute individual counseling sessions.
- Active bupropion , No counseling (Type: ACTIVE_COMPARATOR): Active bupropion, No counseling, only medication checks
- Placebo medication + counseling (Type: PLACEBO_COMPARATOR): Placebo bupropion plus eight 10-minute individual counseling sessions
- Placebo medication, No counseling (Type: PLACEBO_COMPARATOR): Placebo bupropion, No counseling, just medication checks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed renal cell cancer with a component of clear cell subtype, with metastasis~* Evidence of measurable disease~* Must have failed one prior systemic first-line regimen for metastatic renal cell cancer~Exclusion Criteria:~* Prior treatment for metastatic renal cell cancer with more that one systemic first line therapy~* Major surgery less than 4 weeks or radiation less than 2 weeks of starting study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Axitinib (Type: EXPERIMENTAL): None
- Sorafenib (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Local Infiltration Analgesia in Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Physical status according to American Society of Anesthesiologists (ASA) I-III~* Patients scheduled for total knee arthroplasty~Exclusion Criteria:~* Contraindication for central and/or peripheral nervous blockade~* Reoperation on previous total knee arthroplasty~* History of allergic or other adverse reactions on the agents used in the study~* Chronic opioid or gabapentinoid use~* Serious psychiatric, mental and cognitive disorders~* Language barrier~* Difficulty in understanding or using a patient controlled analgesia device

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LIA (Type: ACTIVE_COMPARATOR): Local infiltration analgesia
- sham LIA (Type: SHAM_COMPARATOR): Saline injections

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete